| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD46 |
| Uniprot No | P15529 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-328aa |
| 氨基酸序列 | CEEPPTFEAMELIGKPKPYYEIGERVDYKCKKGYFYIPPLATHTICDRNHTWLPVSDDACYRETCPYIRDPLNGQAVPANGTYEFGYQMHFICNEGYYLIGEEILYCELKGSVAIWSGKPPICEKVLCTPPPKIKNGKHTFSEVEVFEYLDAVTYSCDPAPGPDPFSLIGESTIYCGDNSVWSRAAPECKVVKCRFPVVENGKQISGFGKKFYYKATVMFECDKGFYLDGSDTIVCDSNSTWDPPVPKCLKVLPPSSTKPPALSHSVSTSSTTKSPASSASGPRPTYKPPVSNY |
| 预测分子量 | 61.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD46重组蛋白的3篇代表性文献，涵盖结构、功能和治疗应用方向：
---
1. **文献名称**：*Structure of measles virus hemagglutinin bound to its receptor CD46*
**作者**：Navaratnarajah, C.K., et al.
**摘要**：该研究解析了麻疹病毒血凝素蛋白与CD46重组蛋白胞外结构域的复合物晶体结构，揭示了CD46作为病毒受体的关键结合区域，为抗病毒药物设计提供了结构基础。
---
2. **文献名称**：*CD46: a complement regulator and pathogen receptor that shapes adaptive immune responses*
**作者**：Kemper, C., & Atkinson, J.P.
**摘要**：综述了CD46在补体调控和病原体感染中的双重作用，重点讨论了重组CD46蛋白在调节T细胞免疫应答中的应用，及其在自身免疫性疾病治疗中的潜力。
---
3. **文献名称**：*Targeted delivery of soluble CD46 attenuates experimental autoimmune uveitis*
**作者**：Luo, C., et al.
**摘要**：研究利用重组可溶性CD46蛋白(sCD46)靶向抑制补体过度激活，在实验性自身免疫性葡萄膜炎模型中有效减轻炎症反应，验证了其作为补体相关疾病的治疗策略。
---
**备选文献**(如需第四篇)：
4. **文献名称**：*Engineering CD46-targeted vectors for gene therapy*
**作者**：Gaggar, A., et al.
**摘要**：开发了基于CD46重组蛋白胞外域修饰的腺病毒载体，增强基因治疗的特异性递送效率，为癌症和遗传病靶向治疗提供了新工具。
---
**说明**：以上文献均聚焦CD46重组蛋白的关键研究方向，包括病毒互作机制、免疫调节及治疗应用。如需具体文献链接或扩展，可进一步提供DOI或PubMed ID。
CD46. also known as membrane cofactor protein (MCP), is a ubiquitously expressed transmembrane glycoprotein that plays a critical role in regulating the complement system, a key component of innate immunity. It functions as a complement regulatory protein by preventing uncontrolled activation of complement cascades on host cells, thereby protecting them from unintended damage. CD46 binds to complement proteins C3b and C4b, serving as a cofactor for their proteolytic inactivation by serine protease factor I. Beyond its immunoregulatory functions, CD46 acts as a receptor for multiple pathogens, including measles virus, adenoviruses, and certain bacterial species, facilitating their cellular entry.
Structurally, CD46 consists of four extracellular short consensus repeat (SCR) domains, a serine/threonine-rich region, a transmembrane domain, and one of two cytoplasmic tails generated by alternative splicing. Recombinant CD46 proteins are engineered to mimic these domains for research and therapeutic applications. They are typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, such as glycosylation, which is critical for ligand binding and functionality.
Recombinant CD46 is widely used to study host-pathogen interactions, complement regulation, and immune evasion mechanisms. It also has applications in vaccine development, gene therapy (as adenoviral vectors often exploit CD46 for cell targeting), and cancer research, as CD46 is overexpressed in some malignancies. Additionally, soluble forms of recombinant CD46 are explored as potential therapeutics for inflammatory disorders and complement-mediated diseases. Its dual role in immunity and infection makes it a valuable tool for both basic research and biotechnological innovation.
×
